{
  "id": 19140328,
  "title": "Synthetic chromatin engineering for STAT1 reactivation toward restoring cisplatin sensitivity in breast cancer",
  "url": "https://urgent.news/2026/11/09/synthetic-chromatin-engineering-for-stat1-reactivation-toward",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.11.05.764738v1?rss=1"
  },
  "original_language": "en",
  "account": "Chemoresistant cancers often display altered transcription and chromatin characteristics due to shifts in transcription factor function and accessibility. Research has pinpointed STAT1 as a frequently suppressed transcription factor in cisplatin-resistant breast cancer cells. Utilizing resistant MDA-MB-231 TNBC cells, the team verified reduced STAT1 expression and activity, as well as impaired nuclear translocation, suggesting that STAT1 signaling suppression contributes to chemoresistance in breast cancer.\n\nThe researchers aimed to boost STAT1 activity by facilitating its nuclear entry and transcriptional activation via chromatin engineering. They identified PHF6 as a direct STAT1-binding protein through both computational and laboratory studies. Consequently, they developed Dual Reader 3 (DR3), a synthetic chromatin regulator derived from PHF6 to boost both STAT1 interaction and chromatin engagement through histone H2B ubiquitination.\n\nUpon treatment with DR3, STAT1-associated transcriptional programs, including inflammatory and tumor-suppressive miRNAs, were activated. Mechanistically, DR3 facilitated STAT1 nuclear translocation, activated STAT1 through a non-canonical S727-dependent pathway independent of Tyr701 phosphorylation, and augmented chromatin accessibility at STAT1-responsive regulatory regions through histone H2B ubiquitination. CUT&RUN analysis further demonstrated coordinated transcriptional and epigenetic remodeling linked to DR3-mediated STAT1 activation, including upregulation of HIPK2, which enhanced cisplatin sensitivity by reinforcing the intrinsic DNA damage response.\n\nThe study also explored whether STAT1 reactivation could counteract acquired cisplatin resistance. Intravenous delivery of DR3 reestablished cisplatin sensitivity in resistant breast tumors. By synchronizing STAT1 nuclear translocation with chromatin remodeling, DR3 reinvigorated STAT1-dependent transcriptional programs and restored cisplatin sensitivity in breast cancer. This research establishes transcription factor reactivation via synthetic chromatin engineering as a promising therapeutic approach to surmount chemoresistance in solid tumors.",
  "summary": "Chemoresistant cancers acquire transcriptomic and epigenetic alterations through changes in transcription factor activity and chromatin accessibility. Integrative in silico analyses identified STAT1 as a recurrently suppressed transcription factor in cisplatin-resistant breast cancer. Using cisplatin-resistant triple-negative breast cancer (TNBC) MDA-MB-231 cells, we further confirmed reduced…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}